Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|109|1|174-181

ISSN： 1347-9032

Source： Cancer Science, Vol.109, Iss.1, 2018-01, pp. : 174-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1202-1211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1202-1211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1714-1721

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stability Analysis of the Radiant Cable Suspendome

By  

Advanced Materials Research, Vol. 2014, Iss. 1065, 2015-01 ,pp. : 1240-1244

Trans Tech Publications

Access to resources Recommend Favorite

Prognostic value of 18F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer

By  

Cancer Science, Vol. 106, Iss. 11, 2015-11 ,pp. : 1554-1560

John Wiley & Sons Inc

Access to resources Recommend Favorite